Noninvasive ventilation (NIV) related adverse events

Abstract

Introduction: Home NIV is used to treat chronic respiratory failure. However, side effects are rarely reported in clinical trials. Our aim was to report the incidence of side effects, their severity and consequences on quality of life (QoL) and compliance to NIV. Methods: Retrospective analysis including patients established on home NIV attending an outpatient NIV clinic from 05/2017 to 01/2018 in Rouen University Hospital. Eleven NIV side effects were systematically evaluated using a dedicated chart. Side effects were graded as follow: absent (0 point) to intolerable (4points). Score of all side effects was summed. All patients filled a Severe Respiratory Insufficiency questionnaire (SRI). Results: Out of 490 patients who attended our outpatient clinic, 437 (89%) completed their SRI and a NIV side-effect evaluation. Underlying respiratory disease: obesity hypoventilation syndrome (n :142,32%), COPD-OSA (n:96,22%), COPD (n:81,19%), neuromuscular disease (n:78,18%), chest wall disorder (n:29, 7%) and OSA (n :11,2%). Twenty (5%) patients did not report any side effect. Incidence of side effects are summarised in figure 1. NIV side effects score was 5 [IQ: 3 – 8] out of 44. Side effects score was inversely correlated to SRI score and to compliance to NIV: rho: -0.419 (p Side effects are frequent within home NIV users and impair QoL and compliance.